Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia

    Research output: Contribution to journalArticlepeer-review

    70 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia'. Together they form a unique fingerprint.

    Medicine & Life Sciences

    Chemical Compounds